Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03985943 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
A Phase 3 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 941
- Enrollment target
NCT03985943 is a Phase 3 study that has completed, run by Galderma R&D. The registered enrollment target is 941 participants.
The verdict
NCT03985943, a Phase 3 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 941 participants
- Enrollment target
Study Summary
The main purpose of the study was to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with topical treatments.
Interventions
- DRUG Placebo
- DRUG Nemolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 941 participants |
| Start Date | 2019-06-27 |
| Est. Completion | 2022-08-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03985943
The ClinicalTrials.gov registry entry for NCT03985943 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 941 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03985943 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03985943 about?
NCT03985943 is a clinical study titled "Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis". The main purpose of the study was to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with topical treatments.
What is the current status of trial NCT03985943?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 941 participants. The study started on 2019-06-27. Estimated completion is 2022-08-11.
What interventions are being tested in trial NCT03985943?
The interventions under investigation include: Placebo (DRUG), Nemolizumab (DRUG).
Who is sponsoring clinical trial NCT03985943?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.